The optimized study design and regulatory alignment remove near-term protocol risk and may shorten the path to proof-of-concept data. Monitor site activation and enrollment initiation as the next catalyst; a successful interim analysis could drive significant upside for this $20M market cap biotech.
Price Chart
Executive Summary
Medicus Pharma received FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in men with acute urinary retention. The study enrollment was reduced from ~390 to ~126 patients, potentially accelerating development and reducing capital needs. The FDA's recommendations are operational in nature and do not alter the study's scientific rationale.
Key Facts
- FDA provided written feedback with seven operational recommendations on July 8, 2026, supporting the optimized Phase 2 protocol for Teverelix.
- Central IRB (Advarra) approved the ANT-2111-02 protocol with modifications on June 18, 2026, with approval through June 18, 2027.
- Optimized study will enroll approximately 126 patients, down from the previously contemplated ~390 patients, a ~68% reduction.
- Study is randomized, double-blind, placebo-controlled, multicenter, evaluating Teverelix DP for prevention of recurrent acute urinary retention.
- Primary endpoint is reduction in total prostate volume; includes pre-specified interim analysis for dose optimization.
Financial Impact
Reduction in enrollment from ~390 to ~126 patients likely lowers study costs significantly, though exact savings undisclosed.
Risk Factors
- Study has not yet started enrollment; final site activation and FDA recommendation incorporation remain to be completed.
- No clinical efficacy data have been generated; the study's pharmacodynamic signal may not translate to positive outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328360 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.60 | awaiting T+1 | — | $2.51 (−3.46%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 16, 2026 10d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.51 (−5.46%) |
Oct 7, 2026 19d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.51 (+2363.20%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.51 (+1475.64%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.51 (−1443.67%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.51 (+1455.14%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.51 (+1372.14%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.51 (+518.23%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.51 (−733.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers